Mind Medicine (Mind Medicine) Cash-to-Debt : 7.06 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Mind Medicine Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Mind Medicine's cash to debt ratio for the quarter that ended in Dec. 2023 was 7.06.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Mind Medicine could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Mind Medicine's Cash-to-Debt or its related term are showing as below:

MMCWF' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.06 Med: 5987.1 Max: No Debt
Current: 7.06

During the past 4 years, Mind Medicine's highest Cash to Debt Ratio was No Debt. The lowest was 7.06. And the median was 5987.10.

MMCWF's Cash-to-Debt is ranked better than
50.81% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs MMCWF: 7.06

Mind Medicine Cash-to-Debt Historical Data

The historical data trend for Mind Medicine's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mind Medicine Cash-to-Debt Chart

Mind Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

1,974.19

7.06

Mind Medicine Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial												1,974.19	1,797.35	1,558.60	8.37	7.06

Competitive Comparison of Mind Medicine's Cash-to-Debt

For the Biotechnology subindustry, Mind Medicine's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mind Medicine's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Mind Medicine's Cash-to-Debt falls into.

Mind Medicine Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Mind Medicine's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	99.704	/	(0	+	14.129)
	=	7.06

Mind Medicine's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	99.704	/	(0	+	14.129)
	=	7.06

Mind Medicine (OTCPK:MMCWF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Mind Medicine Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine (Mind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (OTCPK:MMCWF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

MNMD:USA MMQ:Germany MMED:Canada

Address

One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website

https://www.mindmed.co

Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.